Maintenance therapy with cisapride after healing of erosive oesophagitis: A double-blind placebo-controlled trial

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 3, 1997, Pages 487-495

  Mcdougall, N I ^a   Watson, R G P ^a   Collins, J S A ^b   Mcfarland, R J ^c   Love, A H G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c ULSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; OMEPRAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EROSIVE GASTRITIS; ESOPHAGUS MOTILITY; ESOPHAGUS PH; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; MANOMETRY; PH MEASUREMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RELAPSE;

EID: 0030804027     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00176.x     Document Type: Article

References (29)

1. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903-12.
2. Glise H. Healing, relapse rates and prophylaxis of reflux oesophagitis. Scand J Gastroenterol 1989; 24 (Suppl. 156): 57-64.
3. Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut 1995; 36: 492-8.
4. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996; 58: 481-6.
5. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole vs ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590-8.
6. Lundell L, Backman L, Ekstrom P, et al. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991; 26: 248-56.
7. Lamberts R, Creutzfeldt W, Strüber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356-70.
8. Lundell L. Long-term treatment of gastro-oesophageal reflux disease with omeprazole. Scand J Gastroenterol 1994; 29 (Suppl. 201): 74-8.
9. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
10. Lieberman DA. Medical therapy for chronic reflux esophagitis. Long-term follow-up. Arch Intern Med 1987; 147: 1717-20.
11. Ceccatelli P, Janssens J, Vantrappen G, Cucchiara S. Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients. Gut 1988; 29: 631-5.
12. Tytgal GNJ, Anker Hansen OJ, Carling L, Geldof H, Glise H. Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug. Scand J Gastroenterol 1992; 27: 175-83.
13. Toussaint J, Gossuin A, Deruyttere M, Huble F, Devis G. Healing and prevention of relapse of reflux oesophagitis by cisapride. Gut 1991; 32: 1280-5.
14. Blum AL, Adami B, Bouzo MH, et al. Effect of cisapride on relapse of esophagitis: a multinational, placebo controlled trial in patients healed with an antisecretory drug. Dig Dis Sci 1993; 38: 551-60.
15. Little AG, De Meester TR, Kirchner PT, O'Sullivan GC, Skinner DB. Pathogenesis of esophagitis in patients with gastroesophageal reflux. Surgery 1980; 88: 101-7.
16. Dalton CB. Measurements and interpretations. In: Castell DO, Richter JE, Dalton CB, eds. Esophageal Motility Testing. New York: Elsevier, 1987: 61-78.
17. McDougall NI, Kee F, Collins JSA, McFarland RJ, Love AHG. Does treatment of esophagitis with omeprazole improve patient quality of life? Gastroenterology 1995; 108(4): A162 (Abstract).
18. Tytgat GNJ, Blum AL, Verlinden M. Prognostic factors for relapse and maintenance treatment with cisapride in gastrooesophageal reflux disease. Aliment Pharmacol Ther 1995; 9: 271-80.
19. Tytgat GNJ. Long term therapy for reflux esophagitis. N Engl J Med 1995; 333: 1148-50.
20. Poynard T. Relapse rate of patients after healing of oesophagitis - a prospective study of alginate as self-care treatment for 6 months. Aliment Pharmacol Ther 1993; 7: 385-92.
21. Gilbert RJ, Dodds WJ, Kahrilas PJ, Hogan WJ, Lipman S. Effect of cisapride, a new prokinetic agent, on esophageal motor function. Dig Dis Sci 1987; 32(12): 1331-6.
22. Holloway RH, Downton J, Mitchell B, Dent J. Effect of cisapride on postprandial gastro-oesophageal reflux. Gut 1989; 30: 1187-93.
23. Inauen W, Emde C, Weber B, et al. Effects of ranitdine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study. Gut 1993; 34: 1025-31.
24. Brazier JE, Harper R, Jones NMB, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. Br Med J 1992; 305: 160-4.
25. Kuster E, Ros E, Toledo-Pimentel V, et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut 1994; 35: 8-14.
26. Richter JE, Long FJ. Cisapride for gastroesophageal reflux disease: a placebo-controlled, double-blind study. Am J Gastroenterol 1995; 90: 423-30.
27. Baldi F, Bianchi Porro G, Dobrilla G, et al. Cisapride versus placebo in reflux esophagitis: a multicenter double-blind trial. J Clin Gastroenterol 1988; 10(6): 614-8.
28. Lepoutre L, Vanderlinden I, Bollen G, et al. Controlled study of Cisapride in the treatment of grade II and III oesophagitis. Gastroenterology 1987; 92(2): A1501 (Abstract).
29. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.